2025 American Society of Clinical Oncology (ASCO)
ASCO 2025 Prostate Cancer
- ASCO 2025: Phase 3, Randomized, Placebo-Controlled Clinical Trial of CAN-2409 + Prodrug in Combination with Standard of Care External Beam Radiation for Newly Diagnosed Localized Prostate Cancer
- ASCO 2025: How to Get Lutetium-177 PSMA to Those That Will Most Benefit?
- ASCO 2025: Discussion: Tailoring Therapy in Castration-Sensitive Prostate Cancer: Do Biomarkers Make the Cut?
- ASCO 2025: Trials-in-Progress: Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase 2 Multi-Arm Biomarker-Based Study (Alliance A032102)
- ASCO 2025: Radioligand Therapies in Prostate Cancer: Hits, Misses, and Next Steps
ASCO 2025 Bladder Cancer
- ASCO 2025: Intravesical Disitamab Vedotin (RC48) for Patients with HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Dose-Escalation Phase I Trial
- ASCO 2025: Assessing Treatment Outcomes of Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer
- ASCO 2025: Prognostic Utility of ctDNA Before and After Trimodality Therapy (TMT) for Muscle Invasive Bladder Cancer
- ASCO 2025: Treatment Patterns and Clinical Outcomes with Platinum-Based Chemotherapy After Enfortumab Vedotin and Pembrolizumab in Patients with Metastatic Urothelial Carcinoma
- ASCO 2025: IL-15RαFc Superagonist SHR-1501 with or Without Bacille Calmette Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: A Phase 1/2 Study
ASCO 2025 Kidney Cancer
- ASCO 2025: STARLITE-1: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naive Patients with Advanced Clear Cell RCC
- ASCO 2025: A Phase 1/2 First in Human Study of ADI-270, an Armored Allogeneic Anti-CD70 Chimeric Antigen Receptor γδ T Cell Therapy, in Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma
- ASCO 2025: Neoadjuvant Lenvatinib plus Pembrolizumab for Resectable Clear-Cell Renal Cell Carcinoma (PELUR): A Prospective Phase 2 Study
- ASCO 2025: STARLITE 2: Phase 2 Study of Nivolumab plus 177lutetium-Labeled Anti–carbonic Anhydrase IX (CAIX) Monoclonal Antibody Girentuximab (177Lu-Girentuximab) in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- ASCO 2025: Efficacy and Safety of Second-Line Cabozantinib +/ Atezolizumab for Patients with Advanced Renal Cell Carcinoma After Progression on Immuno-Oncology Combinations: Subgroup Analysis of CONTACT-03
ASCO 2025 Testicular and Penile Cancer
ASCO 2025 Upper Tract Urothelial Carcinoma
- ASCO 2025: ENLIGHTED Phase 3 Study: Interim Results of Efficacy and Safety of Padeliporfin VTP Therapy in the Treatment of Low-Grade Upper Tract Urothelial Cancer
- ASCO 2025: The uTRACT Registry: A Single-Arm, Multicenter, Prospective, and Retrospective Registry Study to Evaluate the Real-World Use of UGN-101 in Participants with Upper Tract Urothelial Carcinoma in the United States
ASCO 2025 Press Releases
- Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-altered mCSPC
- Artera Presenting Validation Data at 2025 ASCO Annual Meeting Highlighting How Multimodal AI Platform (MMAI) is Advancing Personalized Cancer Care
- Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
- Bicycle Therapeutics to Present Data in Locally Advanced or Metastatic Urothelial Cancer at ASCO 2025
- ASCO 2025: Phase III ARANOTE Post-Hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (Darolutamide) plus ADT